Kerstin A Kessel1,2,3, Wolfgang Weber4, Igor Yakushev4, Hanna Fischer5, Theresa Voglhuber5, Christian Diehl5,6, Christoph Straube5,6, Claus Zimmer7, Benedikt Wiestler7, Jens Gempt8, Bernhard Meyer8, Stephanie E Combs5,9,6. 1. Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany. kerstin.kessel@tum.de. 2. Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, Ingolstädter Landstraße 1, Neuherberg, Germany. kerstin.kessel@tum.de. 3. Deutsches Konsortium für Translationale Krebsforschung (DKTK), DKTK Partner Site Munich, Munich, Germany. kerstin.kessel@tum.de. 4. Department of Nuclear Medicine, Technical University of Munich (TUM), Ismaninger Straße, 22, Munich, Germany. 5. Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany. 6. Deutsches Konsortium für Translationale Krebsforschung (DKTK), DKTK Partner Site Munich, Munich, Germany. 7. Department of Neuroradiology, Technical University of Munich (TUM), Ismaninger Straße, 22, Munich, Germany. 8. Department of Neurosurgery, Technical University of Munich (TUM), Ismaninger Straße, 22, Munich, Germany. 9. Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, Ingolstädter Landstraße 1, Neuherberg, Germany.
Abstract
PURPOSE: Meningiomas have an excellent survival prognosis, and radiotherapy (RT) is a central component of interdisciplinary treatment. During treatment planning, the definition of the target volume remains challenging using MR and CT imaging alone. This is the first study to analyze the impact of additional PET-imaging on local control (LC) and overall survival (OS) after high-precision RT. METHODS: We analyzed 339 meningiomas treated between 2000 and 2018. For analyses, we divided the patients in low-grade (n = 276) and high-grade (n = 63) cases. We performed RT in an adjuvant setting due to subtotal resection or later due to recurrent tumor growth. The target volumes were delineated based on diagnostic CT and MRI and, if available, additional PET-imaging (low-grade: n = 164, 59.4%; high-grade: n = 39, 61.9%) with either 68Ga-Dotanoc/Dotatoc, 18F-fluoroethyltyrosine or 11C-methionine tracer. Patients were treated with fractionated stereotactic RT with a median total dose and dose per fraction of 54 Gy and 1.8 Gy, respectively. RESULTS: Median follow-up was 5.6 years. For low-grade meningiomas, mean OS was 15.6 years and mean LC was 16.9 years; for high-grade cases mean OS was 11.6 years, and mean LC was 11.1 years. In univariate analyses, PET-imaging had a significant impact on OS (p = 0.035) and LC (p = 0.041) for low-grade meningiomas and remained significant (p = 0.015) for LC in the multivariate analysis. For high-grade cases, PET did not influence both OS and LC. Further prognostic factors could be identified. CONCLUSIONS: For low-grade meningiomas, we showed that the addition of PET-imaging for target volume definition led to a significantly enhanced LC. Thus, PET improves the detection of tumor cells and helps distinguish between healthy tissue and meningioma tissue, especially during the treatment planning process.
PURPOSE:Meningiomas have an excellent survival prognosis, and radiotherapy (RT) is a central component of interdisciplinary treatment. During treatment planning, the definition of the target volume remains challenging using MR and CT imaging alone. This is the first study to analyze the impact of additional PET-imaging on local control (LC) and overall survival (OS) after high-precision RT. METHODS: We analyzed 339 meningiomas treated between 2000 and 2018. For analyses, we divided the patients in low-grade (n = 276) and high-grade (n = 63) cases. We performed RT in an adjuvant setting due to subtotal resection or later due to recurrent tumor growth. The target volumes were delineated based on diagnostic CT and MRI and, if available, additional PET-imaging (low-grade: n = 164, 59.4%; high-grade: n = 39, 61.9%) with either 68Ga-Dotanoc/Dotatoc, 18F-fluoroethyltyrosine or 11C-methionine tracer. Patients were treated with fractionated stereotactic RT with a median total dose and dose per fraction of 54 Gy and 1.8 Gy, respectively. RESULTS: Median follow-up was 5.6 years. For low-grade meningiomas, mean OS was 15.6 years and mean LC was 16.9 years; for high-grade cases mean OS was 11.6 years, and mean LC was 11.1 years. In univariate analyses, PET-imaging had a significant impact on OS (p = 0.035) and LC (p = 0.041) for low-grade meningiomas and remained significant (p = 0.015) for LC in the multivariate analysis. For high-grade cases, PET did not influence both OS and LC. Further prognostic factors could be identified. CONCLUSIONS: For low-grade meningiomas, we showed that the addition of PET-imaging for target volume definition led to a significantly enhanced LC. Thus, PET improves the detection of tumor cells and helps distinguish between healthy tissue and meningioma tissue, especially during the treatment planning process.
Authors: Ali Afshar-Oromieh; Frederik L Giesel; Heinz G Linhart; Uwe Haberkorn; Sabine Haufe; Stephanie E Combs; Dino Podlesek; Michael Eisenhut; Clemens Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2012-06-05 Impact factor: 9.236
Authors: E Zanoletti; A Mazzoni; A Martini; R V Abbritti; R Albertini; E Alexandre; V Baro; S Bartolini; D Bernardeschi; R Bivona; M Bonali; I Borghesi; D Borsetto; R Bovo; M Breun; F Calbucci; M L Carlson; A Caruso; P Cayé-Thomasen; D Cazzador; P-O Champagne; R Colangeli; G Conte; D D'Avella; G Danesi; L Deantonio; L Denaro; F Di Berardino; R Draghi; F H Ebner; N Favaretto; G Ferri; A Fioravanti; S Froelich; A Giannuzzi; L Girasoli; B R Grossardt; M Guidi; R Hagen; S Hanakita; D G Hardy; V C Iglesias; S Jefferies; H Jia; M Kalamarides; I N Kanaan; M Krengli; A Landi; L Lauda; D Lepera; S Lieber; S L K Lloyd; A Lovato; F Maccarrone; R Macfarlane; J Magnan; L Magnoni; D Marchioni; J P Marinelli; G Marioni; V Mastronardi; C Matthies; D A Moffat; S Munari; M Nardone; R Pareschi; C Pavone; E Piccirillo; G Piras; L Presutti; G Restivo; M Reznitsky; E Roca; A Russo; M Sanna; L Sartori; M Scheich; W Shehata-Dieler; D Soloperto; F Sorrentino; O Sterkers; A Taibah; M Tatagiba; G Tealdo; D Vlad; H Wu; D Zanetti Journal: Acta Otorhinolaryngol Ital Date: 2019-06 Impact factor: 2.124
Authors: Kerstin A Kessel; Hanna Fischer; Markus Oechnser; Claus Zimmer; Bernhard Meyer; Stephanie E Combs Journal: Strahlenther Onkol Date: 2017-06-15 Impact factor: 3.621
Authors: Sebastian Adeberg; Christian Hartmann; Thomas Welzel; Stefan Rieken; Daniel Habermehl; Andreas von Deimling; Jürgen Debus; Stephanie E Combs Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-02 Impact factor: 7.038
Authors: Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn Journal: Neuro Oncol Date: 2016-02-09 Impact factor: 12.300
Authors: Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: Lewis A Rosenberg; Richard A Prayson; Joung Lee; Chandana Reddy; Samuel T Chao; Gene H Barnett; Michael A Vogelbaum; John H Suh Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-01 Impact factor: 7.038
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316
Authors: Lorenzo Vagnoni; Sami Aburas; Martina Giraffa; Ivana Russo; Vito Chiarella; Sergio Paolini; Paolo Tini; Giuseppe Minniti Journal: Neurosurg Rev Date: 2022-06-04 Impact factor: 2.800
Authors: Catherine Coolens; Matt N Gwilliam; Paula Alcaide-Leon; Isabella Maria de Freitas Faria; Fabio Ynoe de Moraes Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639
Authors: Hanne-Rinck Jeltema; Marnix R Jansen; Adriaan R E Potgieser; Antoinette D I van Asselt; Mart A A M Heesters; Anouk van de Hoorn; Andor W J M Glaudemans; J Marc C van Dijk Journal: Neuroradiology Date: 2021-03-10 Impact factor: 2.804